- Home
- HOTH vs HBIO Comparison
HOTH vs HBIO Comparison
Compare HOTH & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- HBIO
- Stock Information
- Founded
- HOTH 2017
- HBIO 1901
- Country
- HOTH United States
- HBIO United States
- Employees
- HOTH N/A
- HBIO N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- HOTH Health Care
- HBIO Industrials
- Exchange
- HOTH Nasdaq
- HBIO Nasdaq
- Market Cap
- HOTH 20.9M
- HBIO 24.6M
- IPO Year
- HOTH 2019
- HBIO 2000
- Fundamental
- Price
- HOTH $1.54
- HBIO $0.42
- Analyst Decision
- HOTH Strong Buy
- HBIO Buy
- Analyst Count
- HOTH 3
- HBIO 3
- Target Price
- HOTH $4.00
- HBIO $2.50
- AVG Volume (30 Days)
- HOTH 1.1M
- HBIO 553.3K
- Earning Date
- HOTH 11-11-2025
- HBIO 11-06-2025
- Dividend Yield
- HOTH N/A
- HBIO N/A
- EPS Growth
- HOTH N/A
- HBIO N/A
- EPS
- HOTH N/A
- HBIO N/A
- Revenue
- HOTH N/A
- HBIO $88,750,000.00
- Revenue This Year
- HOTH N/A
- HBIO N/A
- Revenue Next Year
- HOTH N/A
- HBIO $7.02
- P/E Ratio
- HOTH N/A
- HBIO N/A
- Revenue Growth
- HOTH N/A
- HBIO N/A
- 52 Week Low
- HOTH $0.65
- HBIO $0.28
- 52 Week High
- HOTH $3.80
- HBIO $2.82
- Technical
- Relative Strength Index (RSI)
- HOTH 46.54
- HBIO 39.39
- Support Level
- HOTH $1.46
- HBIO $0.41
- Resistance Level
- HOTH $1.72
- HBIO $0.45
- Average True Range (ATR)
- HOTH 0.13
- HBIO 0.02
- MACD
- HOTH -0.03
- HBIO -0.00
- Stochastic Oscillator
- HOTH 20.00
- HBIO 13.20
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.